Hannah M. Nazri

Hannah M. Nazri

Auto-generated profile, based on publicly available information

Hannah M. Nazri

Division of Medical Sciences, Clinical Sciences Research University of Warwick, University Hospital Coventry and Warwickshire Coventry UK

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2023 in Human Reproduction
Verified
Journal Article
Open access
PDF file
HNHannah M Nazri
Hannah M Nazri
EGErin Greaves
Erin Greaves
SQSiobhan Quenby
Siobhan Quenby
RDRebecca Dragovic
Rebecca Dragovic
TTThomas T Tapmeier
Thomas T Tapmeier
CBChristian M Becker
Christian M Becker
Endometriosis is defined by the presence of extrauterine endometrial-like tissue, which can cause pain and infertility in 10% of reproductive-age women. To date, the pathogenesis is poorly understood resulting in significant diagnostic delays and poor therapeutic outcomes in many women. Small extracellular vesicles (sEVs) (<200 nm) are cell-derived vesicles containing molecules that can influence gene expression and behaviour in target cells. One such cargo are microRNAs (miRNAs), which are short, non-coding RNAs mostly 19–25 nucleotides in length that regulate post-transcriptional gene expression. This mini-review focuses on the role of sEV-miRNAs, which are conceivably better biomarkers for endometriosis than free miRNAs, which reflect the true pathophysiological state in the body, as sEV-encapsulated miRNAs are protected from degradation compared to free miRNA and provide direct cell-to-cell communication via sEV surface proteins. sEV-miRNAs have been implicated in the immunomodulation of macrophages, the proliferation, migration and invasion of endometrial cells, and angiogenesis, all hallmarks of endometriosis. The diagnostic potential of sEV-miRNA was investigated in one study that reported the sensitivity and specificity of two sEV-miRNAs (hsa-miR-22-3p and hsa-miR-320a-3p) in distinguishing endometriosis from non-endometriosis cases. Only three studies have explored the therapeutic potential of sEV-miRNAs in vivo in mice—two looked into the role of sEV-hsa-miR-214-3p in decreasing fibrosis, and one investigated sEV-hsa-miR-30c-5p in suppressing the invasive and migratory potential of endometriotic lesions. While early results are encouraging, studies need to further address the potential influence of factors such as the menstrual cycle as well as the location and extent of endometriotic lesions on miRNA expression in sEVs. Given these findings, and extrapolating from other conditions such as cancer, diabetes, and pre-eclampsia, sEV-miRNAs could present an attractive and urgently needed future diagnostic and therapeutic target for millions of women suffering from endometriosis. However, research in this area is hampered by lack of adherence to the International Society for Extracellular Vesicles 2018 guideline in separating and characterising sEVs, as well as the World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project protocols.

24 September 2026 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Open access
HNHannah M. Nazri
Hannah M. Nazri
Roman FischerRoman Fischer
Roman Fischer
JSJoel Steele
Joel Steele
SMSanjiv Manek
Sanjiv Manek
KSKavita S. Subramaniam
Kavita S. Subramaniam
CBChristian M. Becker
Christian M. Becker
Objective: To demonstrate the presence of peritoneal fluid (PF)‐derived small extracellular vesicles (sEVs) in endometriosis and control samples, to characterise their protein content and to define endometriosis‐specific biomarkers within the sEV proteome. Design: Case–control experimental study. Setting: Academic endometriosis centre. Sample: PF samples from women between 18 and 49 years old ( n = 63). Methods: sEVs were enriched using size exclusion chromatography (SEC), and characterised by nanoparticle tracking analysis (NTA), immunoblotting and mass spectrometry, according to surgically‐defined disease stage and cycle phase (control, rASRM stages I–II and III–IV endometriosis, in proliferative, secretory, and menstrual phases). FragPipe was used for protein identification. Main Outcome Measures: Protein content of sEVs from control and endometriosis PF samples. Results: sEVs were identified in PF of women by NTA, immunoblotting and mass spectrometry. Four proteins were significantly different across all samples: fructose‐bisphosphate aldolase A (ALDOA: 3.12‐fold increase in control samples, p = 0.0164), heat shock protein 90‐alpha (HSP90AA1: 2.14‐fold increase in control samples, p = 0.0245), collagen alpha‐1 (XV) chain (COL15A1: 1.83‐fold increase in control samples, p = 0.0421), and protein S100‐A10 (2.54‐fold increase in endometriosis samples, p = 0.0421). Conclusions: PF‐derived sEVs differ between endometriosis and control patients. Concentrations vary regardless of cycle phase and disease stage, and this difference appears to be reflected in the proteomics analysis. However, higher sampling numbers are needed to confirm findings and functional assays to be performed delineate sEV function in endometriosis pathophysiology. Correlating PF‐derived sEV proteins with those in blood or urine could help further understand endometriosis and lead to the identification of biomarkers for diagnosis.